Literature DB >> 17143002

Lp(a) lipoprotein and plasminogen activity in patients with different etiology of ischemic stroke.

Nils H Petersen1, Alexander B Schmied, Jörn A Zeller, Hansjörg Plendl, Günther Deuschl, Peter Zunker.   

Abstract

BACKGROUND AND
PURPOSE: Lp(a) lipoprotein plays an important part in atherothrombogenesis and is considered an independent risk factor for coronary heart disease. However, its role in cerebrovascular disease remains unclear, in particular because of the heterogeneous nature of strokes. We investigated whether elevated Lp(a) is more frequent in ischemic stroke related to atherothrombosis than in other etiologies of stroke. Because of the close structural homology between Lp(a) and plasminogen, we also studied the role of plasminogen in different stroke subtypes and whether there is a dependency on Lp(a) plasma levels.
METHODS: Lp(a) levels and plasminogen activity were measured in 253 consecutive patients with acute ischemic stroke and in 63 controls (CS). Subtypes of stroke were established according to the TOAST criteria.
RESULTS: Median Lp(a) levels were found to be higher in the total cerebral infarction group and in patients with large artery atherosclerosis (LAA) when compared with CS (20.9 and 22.0 mg/dl, respectively, vs. 16.0 mg/dl; p < 0.05). In addition, elevated Lp(a) levels >30 mg/dl were more frequent among the LAA subgroup than among CS (39.4 vs. 11.1%; p < 0.001). Mean plasminogen activity was lower in the total cerebral infarction group (110.8 vs. 120.3%; p < 0.001) and in patients with cardioembolic stroke (109.8 vs. 120.3%; p < 0.05) when compared with CS. There was no correlation between Lp(a) levels and plasminogen activity.
CONCLUSIONS: Our results support the hypothesis that elevated Lp(a) is a risk factor for ischemic stroke and especially for strokes caused by LAA. Low plasminogen activity may play a role in the pathogenesis of cerebrovascular disease, especially for the development of cardioembolic stroke.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17143002     DOI: 10.1159/000097640

Source DB:  PubMed          Journal:  Cerebrovasc Dis        ISSN: 1015-9770            Impact factor:   2.762


  7 in total

1.  Blood biomarkers in cardioembolic stroke.

Authors:  Teresa García-Berrocoso; Israel Fernández-Cadenas; Pilar Delgado; Anna Rosell; Joan Montaner
Journal:  Curr Cardiol Rev       Date:  2010-08

2.  Clinical and genetic features in a family with CADASIL and high lipoprotein (a) values.

Authors:  Maolian Gong; Franz Rueschendorf; Peter Marx; Herbert Schulz; Hans-Georg Kraft; Norbert Huebner; Hans-Christian Koennecke
Journal:  J Neurol       Date:  2010-02-09       Impact factor: 4.849

3.  Increased stroke risk and lipoprotein(a) in a multiethnic community: the Northern Manhattan Stroke Study.

Authors:  Bernadette Boden-Albala; Douglas E Kargman; I-Feng Lin; Myunghee C Paik; Ralph L Sacco; Lars Berglund
Journal:  Cerebrovasc Dis       Date:  2010-07-23       Impact factor: 2.762

4.  Heritable thrombophilia-hypofibrinolysis and osteonecrosis of the femoral head.

Authors:  Charles J Glueck; Richard A Freiberg; Ping Wang
Journal:  Clin Orthop Relat Res       Date:  2008-03-19       Impact factor: 4.176

5.  Proteomics-Based Approach to Identify Novel Blood Biomarker Candidates for Differentiating Intracerebral Hemorrhage From Ischemic Stroke-A Pilot Study.

Authors:  David Malicek; Ilka Wittig; Sebastian Luger; Christian Foerch
Journal:  Front Neurol       Date:  2021-12-17       Impact factor: 4.003

6.  Association between paraoxonase gene and stroke in the Han Chinese population.

Authors:  Guojun Zhang; Wenjin Li; Zhiqiang Li; Hong Lv; Yonghong Ren; Ruimin Ma; Xiaohong Li; Xixiong Kang; Yongyong Shi; Yimin Sun
Journal:  BMC Med Genet       Date:  2013-01-28       Impact factor: 2.103

7.  Lipoprotein (a) level as a risk factor for stroke and its subtype: A systematic review and meta-analysis.

Authors:  Pradeep Kumar; Priyanka Swarnkar; Shubham Misra; Manabesh Nath
Journal:  Sci Rep       Date:  2021-08-02       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.